<DOC>
	<DOCNO>NCT03101878</DOCNO>
	<brief_summary>The purpose ass Safety , Tolerability , Pharmacokinetics , Pharmacodynamics IONIS AGT-LRx Healthy Volunteers Hypertensive Patients Blood Pressure Controlled ACE Inhibitors ARBs</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Ionis AGT-LRx Healthy Volunteers Hypertensive Patients With Blood Pressure Controlled ACE Inhibitors ARBs</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Must give write informed consent able comply study requirement Healthy male female age 1860 inclusive weigh ≥ 50 kg time Informed Consent Females must nonpregnant nonlactating , either surgically sterile post menopausal Males must surgically sterile , abstinent use acceptable contraceptive method BMI ≤ 35 kg/m Agree conduct home blood pressure monitoring ( triplicate use study provide device ) every morning every evening throughout study participation For hypertensive patient enrol trial : At Screening , subject must stable regimen antihypertensive medication ( ) least 1 month prior Screening , 1 follow category : Single angiotensinconverting enzyme inhibitor ( ACEi ) b . A single ARB c. Either ACEi ARB , single antihypertensive medication ( example beta blocker , calcium channel blocker diuretic medication ) d. Antihypertensive treatment naïve subject may eligible follow approval Sponsor Medical Monitor At Screening , office seat blood pressure ( confirmed triplicate ) must within follow range 2 additional test allow order qualify 1 . Subject control antihypertensive medication office seat blood pressure must ≥ 130 ≤ 150 mmHg systolic ≥ 60 ≤ 90 mmHg diastolic OR 2 . Antihypertensive medication treatment naïve subject must ≥140 ≤160 mmHg systolic ≥ 80 ≤ 100 mmHg diastolic Subject must diagnose essential hypertension minimum 6 month prior screen . Subject document stable hypertension short period 6 month may eligible follow approval Sponsor Medical Monitor Subject must use centrally act medication treatment hypertension ( e.g. , clonidine , guanfacine , guanabenz , alphamethyldopa ) Subject must use vasodilator treatment hypertension ( e.g. , hydralazine , minoxidil , sodium nitroprusside , diazoxide ) Treatment another Study Drug , biological agent , device within onemonth Screening Subject orthostatic hypotension define fall systolic blood pressure least 20 mmHg diastolic blood pressure least 10 mmHg assume stand position ( within 3 minute stand ) Use nicotinecontaining product illicit drug Considered unsuitable inclusion Principal Investigator History bleed diathesis coagulopathy Use oral parenteral anticoagulant For hypertensive patient enrol trial : Unwilling 1 ) discontinue antihypertensive mediation washout treatment period study 2 ) conduct runin period treatment naïve hypertensive patient Subject secondary hypertension Displays evidence volume depletion ( i.e. , symptom orthostatic hypotension , low urine output increase thirst ) screen prior dose Study Day 1 Subject anticipates use sildenafil ( Viagra ) , tadalafil ( Cialis ) , vardenafil ( Levitra ) investigational treatment period 4 week last dose Subject us anticipate use organic nitrate preparation ( e.g. , nitroglycerin , isosorbide mononitrate , isosorbide dinitrate pentaerythritol ) course study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension , ISIS 757456</keyword>
</DOC>